Glenmark advances Phase 3 trial for ovarian cancer drug
Glenmark advances Phase 3 trial for ovarian cancer drug. The company has progressed its multi-country Phase 3 clinical trial of Trastuzumab rezetecan in platinum-resistant ovarian cancer. This advancement signals positive momentum in its oncology pipeline. Phase 3 trials are pivotal for regulatory approval and market potential.
📊 STOCKS: GLENMARK | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #ClinicalTrial
This brief is AI-generated from public news sources for informational purposes only. Not investment advice. Always consult a SEBI-registered advisor before trading.
Next articlerupee strength backed by bop surplus